Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
We have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse communities we serve.
We offer diagnostic and treatment options for common and complex medical conditions.
Search for condition information or for a specific treatment program.
We are committed to providing expert care—safely and effectively. Let us help you navigate your in-person or virtual visit to Mass General.
At Mass General, the brightest minds in medicine collaborate on behalf of our patients to bridge innovation science with state-of-the-art clinical medicine.
Press Release5 Minute ReadFeb | 24 | 2022
Our study showed these individuals had higher inflammatory markers and more frequently required admission to hospital ICUs than COVID-19 patients with pre-existing diabetes.
BOSTON – Many COVID-19 patients newly diagnosed with diabetes during hospital admission may in fact have a temporary form of the disease related to the acute stress of the viral infection and may return to normal blood sugar levels soon after discharge, a study by Massachusetts General Hospital (MGH) has found. These patients are more likely to be younger, non-white, and on Medicaid or uninsured compared to individuals with previously diagnosed diabetes, suggesting many of these “new-onset” cases may simply be pre-existing but undiagnosed diabetes in individuals with limited access to healthcare services, according to the study published in Journal of Diabetes and Its Complications.
High rates of newly diagnosed diabetes mellitus (NDDM) have been reported in COVID-19 hospital admissions around the world. It is still unclear, however, if this phenomenon represents truly new diabetes or previously undiagnosed cases, what the cause of these elevated blood sugars may be, and whether patients’ blood sugars improve after resolution of COVID-19 infection. Pre-existing diabetes in people with COVID-19 has been associated with higher rates of hospitalization, intensive care unit (ICU) admission, mechanical ventilation, and death.
“We believe that the inflammatory stress caused by COVID-19 may be a leading contributor to ‘new-onset’ or newly diagnosed diabetes,” says lead author Sara Cromer, MD, an investigator with the Department of Medicine-Endocrinology, Diabetes and Metabolism at MGH. “Instead of directly causing diabetes, COVID-19 may push patients with pre-existing but undiagnosed diabetes to see a physician for the first time, where their blood sugar disorder can be clinically diagnosed. Our study showed these individuals had higher inflammatory markers and more frequently required admission to hospital ICUs than COVID-19 patients with pre-existing diabetes.”
For its study, the MGH team looked at 594 individuals who exhibited signs of diabetes mellitus when admitted to MGH at the height of the pandemic in the spring of 2020. Of that group, 78 had no known diagnosis of diabetes prior to admission. Researchers learned that many of these newly diagnosed patients — versus those with pre-existing diabetes — had less severe blood sugar levels but more severe COVID-19. Follow-up with this cohort after hospital discharge revealed that roughly half its members reverted to normal blood sugar levels and that only eight percent required insulin after one year.
“This suggests to us that newly diagnosed diabetes may be a transitory condition related to the acute stress of COVID-19 infection,” explains Cromer. Indeed, this key finding supports the clinical argument that newly diagnosed diabetes is likely caused by insulin resistance — the inability of cells to properly absorb blood sugar in response to insulin, resulting in higher-than- normal build-up of glucose in the blood – rather than by insulin deficiency, caused by direct and permanent injury to the beta cells which manufacture insulin.
“Our results suggest that acute insulin resistance is the major mechanism underlying newly diagnosed diabetes in most patients with COVID-19, and that insulin deficiency, if it occurs at all, is generally not permanent,” says Cromer. “These patients may only need insulin or other medications for a short time, and it’s therefore critical that physicians closely follow them to see if and when their conditions improve.”
Cromer is an instructor in Medicine at Harvard Medical School (HMS). Senior author Deborah Wexler, MD, is an associate professor of Medicine at HMS, associate clinical chief of the MGH Diabetes Unit, and clinical director of the MGH Diabetes Center. Co-author Melissa Putman, MD, is assistant professor of Pediatrics at HMS and an attending physician in Endocrinology at MGH.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World Report list of “America’s Best Hospitals.”
Sara Jane Cromer, MD
Deborah Wexler, MD
Unlike other mitochondrial diseases, this form leads to hyperactive mitochondria—causing patients to have low body weight despite excessive food intake.
Tool will have important research applications and may eventually improve medical therapies that are ineffective when oxygen levels are low.
Topline results in adults with amyotrophic lateral sclerosis (ALS) from Regimen C evaluating CMN-Au8, developed by Clene Nanomedicine, Inc., a suspension of gold nanocrystals to enhance neuronal energy production and utilization
The HEALEY ALS Platform Trial led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) today announced topline results from Regimen C evaluating CMN-Au8, developed by Clene Nanomedicine, Inc.
The wrist-worn devices may identify patients who would benefit from stroke prevention therapies.
Researchers from Mass General and colleagues have used an innovative organoid-on-a-chip model to identify new treatment targets for an inherited kidney disease that causes significant death and disability.
We use cookies and other tools to enhance your experience on our website and to analyze our web traffic. For more information about these cookies and the data collected, please refer to our Privacy Policy.
Explore fellowships, residencies, internships and other educational opportunities.
Learn about career opportunities, search for positions and apply for a job.
Get the latest news, explore events and connect with Mass General.
Learn about the many ways you can get involved and support Mass General.
Copyright © 2007-2022. The General Hospital Corporation.